Practical implication
PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance regarding ambient voice technology (AVT) products used in health settings. This guidance differentiates between AVT products solely for transcription (not regulated) and those for diagnosis, treatment, or prevention (regulated). Manufacturers must evaluate their AVT products accordingly to ensure compliance with medical device vigilance reporting requirements.
What changed: Manufacturers and NHS organizations must classify AVT products based on intended use, with transcription tools not regulated as medical devices, while those supporting diagnosis or treatment must comply with medical device regulations.
Why it matters: This guidance provides critical clarity on the regulatory framework for AVT tools, facilitating safer implementation within the NHS and ensuring that products are appropriately classified for compliance.
Practical implication: PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.
View original source
Published from the Firecrawl policy change extraction pipeline.